• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Mineralys Therapeutics Inc.

    3/9/26 5:15:52 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MLYS alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001672659
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Mineralys Therapeutics, Inc.
    SEC File Number
    001-41614
    Address of Issuer
    150 N. RADNOR CHESTER RD.
    SUITE F200
    RADNOR
    PENNSYLVANIA
    19087
    Phone
    (888) 378-6240
    Name of Person for Whose Account the Securities are To Be Sold
    Rodman David Malcom
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common stock
    Merrill Lynch
    225 Liberty St
    Floor 37
    New York � NY � 10281
    217158269.647913995603/09/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common stock03/09/2026Exercise of employee stock optionsMineralys Therapeutics, Inc.Checkbox not checked217103/09/2026Broker assisted cashless exercise

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    David Rodman
    150 N. RADNOR CHESTER ROAD
    SUITE F200
    RADNOR � PA � 19087
    Common stock01/05/20261927156749100.06
    David Rodman
    150 N. RADNOR CHESTER ROAD
    SUITE F200
    RADNOR � PA � 19087
    Common stock01/02/2026700372511919.03
    David Rodman
    150 N. RADNOR CHESTER ROAD
    SUITE F200
    RADNOR � PA � 19087
    Common stock01/09/2026217072195.90
    David Rodman
    150 N. RADNOR CHESTER ROAD
    SUITE F200
    RADNOR � PA � 19087
    Common stock01/12/20266348205142.99
    David Rodman
    150 N. RADNOR CHESTER ROAD
    SUITE F200
    RADNOR � PA � 19087
    Common stock01/13/20267709252469.75
    David Rodman
    150 N. RADNOR CHESTER ROAD
    SUITE F200
    RADNOR � PA � 19087
    Common stock01/14/202611367370645.39
    David Rodman
    150 N. RADNOR CHESTER ROAD
    SUITE F200
    RADNOR � PA � 19087
    Common Stock01/20/202641613353.60
    David Rodman
    150 N. RADNOR CHESTER ROAD
    SUITE F200
    RADNOR � PA � 19087
    Common Stock02/09/2026217165585.91
    David Rodman
    150 N. RADNOR CHESTER ROAD
    SUITE F200
    RADNOR � PA � 19087
    Common Stock02/12/20266349184076.52
    David Rodman
    150 N. RADNOR CHESTER ROAD
    SUITE F200
    RADNOR � PA � 19087
    Common Stock02/16/202614055385732.29
    David Rodman
    150 N. RADNOR CHESTER ROAD
    SUITE F200
    RADNOR � PA � 19087
    Common Stock02/17/202641711505.03

    144: Remarks and Signature

    Remarks
    Date of Notice
    03/09/2026
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    09/29/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    David Rodman

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $MLYS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MLYS

    DatePrice TargetRatingAnalyst
    6/11/2025$15.00Hold
    Jefferies
    7/10/2024$30.00Buy
    H.C. Wainwright
    4/2/2024$30.00Buy
    Goldman
    3/7/2023Outperform
    Evercore ISI
    3/7/2023$39.00Buy
    BofA Securities
    3/7/2023$32.00Buy
    Guggenheim
    3/7/2023$27.00Overweight
    Wells Fargo
    3/7/2023$45.00Buy
    Stifel
    More analyst ratings

    $MLYS
    SEC Filings

    View All

    SEC Form 144 filed by Mineralys Therapeutics Inc.

    144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    3/9/26 5:15:52 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mineralys Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)

    3/9/26 4:36:20 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Mineralys Therapeutics Inc.

    144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    2/17/26 4:05:07 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results

    – The FDA assigned a PDUFA target action date of December 22, 2026 – – The NDA is based on positive data from a successful clinical program demonstrating favorable safety and blood pressure reduction in adults with hypertension – – Topline results from the Phase 2 Explore-OSA exploratory trial did not reduce AHI; demonstrated a clinically meaningful reduction in blood pressure and favorable safety and tolerability in this population with difficult to control hypertension – RADNOR, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic

    3/9/26 4:30:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026

    RADNOR, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2025, after the financial markets close on Thursday, March 12, 2026. Thursday, March 12th @ 4:30 p.m. ETDomestic:1-877-704-4453International:1-201-389-0920Conference ID:13758574Webcast:Link A live webcast of the conference call may also be found on the "News & Eve

    3/9/26 8:00:00 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

    The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (Boehringer Ingelheim), Lorundrostat (Mineralys Therapeutics), Rilparencel (ProKidney), DISC-0974 (Disc Medicine), Vonsetamig (Regeneron Pharmaceuticals), and others will further boost the market growth.LAS VEGAS, March 3, 2026 /PRNewswire/ -- Recently published Chronic Kidney Disease Market Insights repor

    3/3/26 5:31:00 PM ET
    $AMGN
    $IRON
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $MLYS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Mineralys Therapeutics with a new price target

    Jefferies initiated coverage of Mineralys Therapeutics with a rating of Hold and set a new price target of $15.00

    6/11/25 7:54:20 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Mineralys Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00

    7/10/24 7:50:59 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Mineralys Therapeutics with a new price target

    Goldman initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00

    4/2/24 7:34:24 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Warren Eric claimed ownership of 38,400 shares (SEC Form 3)

    3 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    3/4/26 7:25:12 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. was granted 6,200 shares (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    2/20/26 7:49:59 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sblendorio Glenn was granted 6,200 shares (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    2/20/26 7:47:36 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Akkaraju Srinivas bought $14,999,992 worth of shares (588,235 units at $25.50) (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    9/8/25 8:07:14 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $29,999,985 worth of shares (1,176,470 units at $25.50) (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    9/8/25 5:59:46 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Slingsby Brian Taylor bought $3,499,996 worth of shares (259,259 units at $13.50) (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    4/25/25 7:01:59 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Leadership Updates

    Live Leadership Updates

    View All

    Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer

    RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointment of Minji Kim, Ph.D. as Chief Business Officer. Adam Levy will remain in his role as Chief Financial Officer. "With our expanding operations, we have decided to split the functions of Chief Financial Officer and Chief Business Officer into two roles, and we are excited to have Minji join our team. She brings a solid track record of generating value for multiple companies by identify

    1/4/24 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy

    LOS ANGELES, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Praxis Bioresearch ("Praxis"), a biopharmaceutical company focused on the discovery and development of therapeutics for chronic neuropsychiatric and neurodegenerative disorders with an initial focus on apathy in Alzheimer's Disease, today announced the appointment of Adam Levy to its Board of Directors (the "Board"). Mr. Levy brings executive, financial and operational leadership experience in biopharmaceuticals. "We are excited to have Adam join our Board and support our mission to improve the lives of patients with Alzheimer's Disease," said Sandeep Patil, MD PhD, chief executive officer of Praxis Bioresearch. "Adam brings an impressive

    9/19/23 4:00:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

    SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    11/13/24 4:27:48 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

    SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    11/13/24 4:19:46 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

    SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    11/13/24 4:09:56 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Financials

    Live finance-specific insights

    View All

    Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026

    RADNOR, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2025, after the financial markets close on Thursday, March 12, 2026. Thursday, March 12th @ 4:30 p.m. ETDomestic:1-877-704-4453International:1-201-389-0920Conference ID:13758574Webcast:Link A live webcast of the conference call may also be found on the "News & Eve

    3/9/26 8:00:00 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    – Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 – – Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced financial results for the third quarter ended September 30, 2025, and provided a corporate update. "We are at an excitin

    11/10/25 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025

    RADNOR, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2025, after the financial markets close on Monday, November 10, 2025. Monday, November 10th @ 4:30 p.m. ETDomestic:1-877-704-4453International:1-201-389-0920Conference ID:13756051Webcast:Webcast Link A live webcast of the conference call may also be found on the "

    11/3/25 8:00:00 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care